Drug Delivery Systems
More Bioavailability, Less Side-Effects
NanoHarmonics is working with several biotech companies to develop, do clinical trials, secure regulatory compliance approvals, and commercialize improved drugs. We aim to reformulate and repurpose existing medicines for oncology, for infectious diseases as well as develop new ones in partnership with other pharmaceutical companies.
Our Quantum Dot bio-diagnostics technology will help accelerate the drug development process by bringing the capability to monitor the trends of target biomarkers affected by active pharmaceutical ingredients and their combination.
“That our generation has the capability to work with the smallest kernels of our existence is truly astounding. To use atoms to measure biomarkers…then to use bits to organize and secure the data into useful information…then use those information to develop drug delivery systems that will benefit mankind. It’s the convergence of technologies based on discoveries surrounding the atom, the bit, and the cell that will drive the next technological revolution in our society.”
We have the foundational technology to develop rapid and quantitative diagnostics tests for different biomarkers using Quantum Dots. The quantitative features as well as the accuracy levels of our tests make them ideal for immunity level detection, biomarker monitoring in drug development, infectious diseases management through population studies for predictive models, and biomarkers trends monitoring for personal health.
We are developing a companion secured and encrypted data platform for our Quantum Dot diagnostics. Numerical data from test results will be organized and managed to allow people to monitor trends of biomarkers associated with their health concerns, anonymized positive or negative population data for infectious diseases management, and monitor biomarkers to accelerate drug development for pharmaceutical companies.
We are partnering with several companies who bring novel drug delivery systems that will benefit from our Quantum Dot diagnostics technology and our data platform to participate in population studies that we are spearheading to create predictive models for infectious diseases. We are helping in the formulation of new drugs with potential increases in the bioavailability of beneficial APIs while substantially reducing toxicity and side effects.